Full Text View
Tabular View
No Study Results Posted
Related Studies
Journey for Control of Diabetes Study
This study is ongoing, but not recruiting participants.
First Received: March 31, 2008   Last Updated: July 21, 2009   History of Changes
Sponsored by: Merck
Information provided by: Merck
ClinicalTrials.gov Identifier: NCT00652509
  Purpose

Behavior change and self-efficacy are key for patients with diabetes to sustain blood sugar goals, but most care systems do not provide effective support to assist patients in successful ongoing self-management. After initial education, many programs are limited by allowable Medicare reimbursement for diabetes education which currently requires physician referral and cannot exceed two hours of training per year for a beneficiary, plus one hour of nutritional services. These services are usually provided either on an individual basis or occasionally through a traditional group class approach. For patients with established type 2 diabetes who are not achieving optimal glycemic control, we propose to develop and formally evaluate in a randomized trial a novel group experience to educate and motivate patients with established type 2 called IDEA, (Interactive Dialogue to Educate and Activate). This multi-site, randomized, prospective trial will randomize 621 patients with inadequately blood sugar control levels to one of 3 study groups: (1) IDEA - patients receive group sessions totaling 8 hours, with an average of 10 patients per group, using conversation maps as a conduit to facilitate dialogue between providers and patients (2) Individual Education (IE) - patients receive 2 hours with a nurse educator and 1 hour with a dietitian, and (3) Usual care (UC)- patients receive no research intervention. The primary analyses will involve mixed model regression to assess whether IDEA improves outcomes compared to IE and UC. Blood sugar level, blood pressure, and lipids will be evaluated 6 and12 months post-randomization and behavioral, emotional, and satisfaction outcomes through survey at baseline, 3, 6, 9 and 12 months. Depending on 12 month results, a longitudinal four year post intervention analysis is planned to assess sustainability of treatment effects and cost-effectiveness.


Condition Intervention
Type 2 Diabetes Mellitus
Behavioral: Interactive Dialogue to Educate and Activate (IDEA)
Behavioral: Individual Education (IE)
Behavioral: Usual care (UC)

Study Type: Interventional
Study Design: Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Official Title: Journey for Control of Diabetes Study

Resource links provided by NLM:


Further study details as provided by Merck:

Primary Outcome Measures:
  • Program satisfaction, behavioral and emotional outcomes. [ Time Frame: 3, 6, 9, 12 months after implementation of intervention ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Blood sugar level, blood pressure, lipids, cost, comorbidities. [ Time Frame: 6, 12, 18, 24, 36, and 48 months after intervention ] [ Designated as safety issue: No ]

Estimated Enrollment: 671
Study Start Date: May 2008
Estimated Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental
IDEA
Behavioral: Interactive Dialogue to Educate and Activate (IDEA)
IDEA - patients receive group sessions totaling 8 hours, with an average of 10 patients per group, using conversation maps as a conduit to facilitate dialogue between providers and patients.
2: Active Comparator
IE
Behavioral: Individual Education (IE)
IE - patients receive 2 hours with a nurse educator and 1 hour with a dietitian.
3: No Intervention
UC
Behavioral: Usual care (UC)
UC - patients receive no research intervention.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type 2 Diabetes Mellitus

Exclusion Criteria:

  • Gestational diabetes
  • Type 1 Diabetes Mellitus
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00652509

Sponsors and Collaborators
Merck
Investigators
Principal Investigator: HealthPartners Investigators/Collaborators
Principal Investigator: Lovelace Clinic Foundation Investigators/Collaborators
Study Director: Medical Monitor Merck
  More Information

No publications provided

Responsible Party: Merck & Co., Inc. ( Executive Vice President, Clinical and Quantitative Sciences )
Study ID Numbers: 2008_510, MK0431-111
Study First Received: March 31, 2008
Last Updated: July 21, 2009
ClinicalTrials.gov Identifier: NCT00652509     History of Changes
Health Authority: United States: Food and Drug Administration

Study placed in the following topic categories:
Metabolic Diseases
Diabetes Mellitus, Type 2
Diabetes Mellitus
Endocrine System Diseases
Endocrinopathy
Glucose Metabolism Disorders
Metabolic Disorder

Additional relevant MeSH terms:
Metabolic Diseases
Diabetes Mellitus, Type 2
Diabetes Mellitus
Endocrine System Diseases
Glucose Metabolism Disorders

ClinicalTrials.gov processed this record on September 10, 2009